Anatara's CEO, Steve Lydeamore will be presenting to investors during the Bioshares Biotech Summit this Friday, and at a Monsoon Communications Twilight Investor Briefing event in Melbourne during August.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a SPEC BUY rating and a 12-month price target of $0.90 per share.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets with potential application in other livestock animals, aquaculture and companion animals.
Anatara Lifesciences (ASX:ANR) releases the presentation which Chief Executive Officer, Mr Steven Lydeamore, will present to investors in Perth this week and to the Gold Coast Investment Showcase later this month.
Anatara Lifesciences (ASX:ANR) announces that Zoetis Inc. has given notice of termination of the exclusive worldwide license of Detach(R) for livestock and horses. Zoetis made a portfolio decision not to continue with the pursuit of this asset.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to invite existing and potential shareholders to attend an information briefing session in Perth to discuss the Company's work in gastrointestinal health and to meet Chief Executive Officer, Steven Lydeamore.
In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
